Cargando…

Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA

OBJECTIVES: External validity, or generalisability, is the measure of how well results from a study pertain to individuals in the target population. We assessed generalisability, with respect to socioeconomic status, of estimates from a matched case–control study of 13-valent pneumococcal conjugate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Link-Gelles, Ruth, Westreich, Daniel, Aiello, Allison E, Shang, Nong, Weber, David J, Rosen, Jennifer B, Motala, Tasneem, Mascola, Laurene, Eason, Jeffery, Scherzinger, Karen, Holtzman, Corinne, Reingold, Arthur L, Barnes, Meghan, Petit, Susan, Farley, Monica M, Harrison, Lee H, Zansky, Shelley, Thomas, Ann, Schaffner, William, McGee, Lesley, Whitney, Cynthia G, Moore, Matthew R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724195/ https://www.ncbi.nlm.nih.gov/pubmed/28851801 http://dx.doi.org/10.1136/bmjopen-2017-017715

Ejemplares similares

Bias with respect to socioeconomic status: A closer look at zip code matching in a pneumococcal vaccine effectiveness study
por: Link-Gelles, Ruth, et al.
Publicado: (2016)

Detection of Novel Rotavirus Strain by Vaccine Postlicensure Surveillance
por: Weinberg, Geoffrey A., et al.
Publicado: (2013)

Postlicensure herpes zoster vaccine effectiveness: systematic review protocol
por: Mbinta, James F, et al.
Publicado: (2021)

Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006–2017
por: Neha, Reddy, et al.
Publicado: (2020)

An Assessment of the Screening Method to Evaluate Vaccine Effectiveness: The Case of 7-Valent Pneumococcal Conjugate Vaccine in the United States
por: Cohen, Adam L., et al.
Publicado: (2012)

1474. Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Non-bacteremic Pneumococcal Pneumonia (NBPP) among Adults in the United States, 2013-2017
por: Gierke, Ryan, et al.
Publicado: (2020)

70. Changes in Invasive Pneumococcal Disease among Adults Living with HIV Following Introduction of 13-Valent Pneumococcal Conjugate Vaccine, 2008–2018
por: Matanock, Almea, et al.
Publicado: (2021)

Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
por: Nelson, Jennifer C, et al.
Publicado: (2022)

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
por: Hesse, Elisabeth M., et al.
Publicado: (2019)

Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States
por: Stokley, Shannon, et al.
Publicado: (2014)

Licensing Examination and Crash Outcomes Postlicensure in Young Drivers
por: Walshe, Elizabeth A., et al.
Publicado: (2022)

Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review
por: Mesfin, Yonatan Moges, et al.
Publicado: (2019)

Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013 — United States
por: Stokley, Shannon, et al.
Publicado: (2013)

Statistical Power for Postlicensure Medical Product Safety Data Mining
por: Maro, Judith C., et al.
Publicado: (2017)

1718. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study
por: Andrejko, Kristin, et al.
Publicado: (2023)

1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
por: Pilishvili, Tamara, et al.
Publicado: (2020)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
por: Leach, Amanda Jane, et al.
Publicado: (2014)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
por: Wasserman, Matthew, et al.
Publicado: (2018)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Changes in invasive pneumococcal disease among adults living with HIV following introduction of 13-valent pneumococcal conjugate vaccine, 2008–2014
por: Kobayashi, Miwako, et al.
Publicado: (2017)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
por: Belmonti, Simone, et al.
Publicado: (2019)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status
por: Madhi, Shabir A., et al.
Publicado: (2017)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
por: Esposito, Susanna, et al.
Publicado: (2015)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
por: MacIntyre, C. Raina, et al.
Publicado: (2014)

Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
por: van Westen, Els, et al.
Publicado: (2018)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9j9v13fmdeiu8rtn034d6gvjge